Literature DB >> 26091800

Watershed Hepatocellular Carcinomas: The Risk of Incomplete Response following Transhepatic Arterial Chemoembolization.

Nishita Kothary1, Chris Takehana2, Kerstin Mueller3, Patrick Sullivan4, Ali Tahvildari3, Vishal Sidhar5, Jarrett Rosenberg3, John D Louie6, Daniel Y Sze6.   

Abstract

PURPOSE: Hepatocellular carcinomas (HCCs) bridging two or more Couinaud-Bismuth segments of the liver ("watershed tumors") can recruit multiple segmental arteries. The primary hypothesis of this study was that fewer watershed tumors show complete response (CR) after chemoembolization, with shorter time to local recurrence. Secondary analysis on the impact on transplantation eligibility in the presence of progressive disease was also performed.
MATERIALS AND METHODS: A total of 155 transplantation-eligible patients whose HCC met Milan criteria (watershed, n = 83; nonwatershed, n = 72) and was treated with chemoembolization were included. Cone-beam computed tomography (CT) was used for guidance and for confirmation of circumferential uptake. Local response to chemoembolization per modified Response Evaluation Criteria In Solid Tumors and local disease-free survival (DFS) for the index tumor were calculated. Differences were assessed by univariate and multivariate analyses.
RESULTS: CR after a single of chemoembolization was observed in 55.4% of watershed tumors and in 72.2% of nonwatershed tumors (P = .045). Estimated DFS intervals were 151 days (95% confidence interval [CI], 93-245 d) and 336 days (95% CI, 231-747 d; P = .040) in the watershed and nonwatershed groups, respectively. Worse DFS was observed with a Model for End-Stage Liver Disease score > 20 (P = .0001), higher Child-Pugh-Turcotte score (P = .049), and watershed location (P = .040). Waiting list drop-off rates were statistically similar between groups.
CONCLUSIONS: Hepatocellular carcinomas located in the watershed region of the liver have a poorer response to chemoembolization than those located elsewhere. These tumors are associated with worse DFS and require additional treatments to maintain transplantation eligibility per Milan criteria. Cone-beam CT can identify crossover supply and confirm complete geographic drug uptake, possibly reducing (but not eliminating) the risk of incomplete response.
Copyright © 2015 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26091800     DOI: 10.1016/j.jvir.2015.04.030

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  5 in total

1.  Hepatic Arterial Embolization Using Cone Beam CT with Tumor Feeding Vessel Detection Software: Impact on Hepatocellular Carcinoma Response.

Authors:  F H Cornelis; A Borgheresi; E N Petre; E Santos; S B Solomon; K Brown
Journal:  Cardiovasc Intervent Radiol       Date:  2017-08-02       Impact factor: 2.740

Review 2.  Intra- and Extrahepatic Collaterals: Pitfalls and Pathways for Locoregional Therapy.

Authors:  James Su; Suraj Kapoor; Daniel B Brown
Journal:  Semin Intervent Radiol       Date:  2018-04-05       Impact factor: 1.513

3.  Limitations of Fluorine 18 Fluoromisonidazole in Assessing Treatment-induced Tissue Hypoxia after Transcatheter Arterial Embolization of Hepatocellular Carcinoma: A Prospective Pilot Study.

Authors:  Rajesh P Shah; Paul F Laeseke; Lewis K Shin; Frederick T Chin; Nishita Kothary; George M Segall
Journal:  Radiol Imaging Cancer       Date:  2022-05

4.  Assessment in the Survival Outcome After Transarterial Chemoembolization Combined with Cryoablation for Hepatocellular Carcinoma (Diameter > 4cm) Based on the Albumin-Bilirubin Grade and Platelet-Albumin-Bilirubin ‎grade: ‎ A Preliminary Study.

Authors:  Zhimei Huang; Mengxuan Zuo; Jiayan Ni; Yangkui Gu; Tianqi Zhang; Yiquan Jiang; Shuiqing Zhuo; Chao An; Jinhua Huang
Journal:  Cancer Manag Res       Date:  2020-02-25       Impact factor: 3.989

5.  In Vitro Model for Simulating Drug Delivery during Balloon-Occluded Transarterial Chemoembolization.

Authors:  Jorge Aramburu; Raúl Antón; Junichi Fukamizu; Daiki Nozawa; Makoto Takahashi; Kouji Ozaki; Juan Carlos Ramos; Bruno Sangro; José Ignacio Bilbao; Kosuke Tomita; Tomohiro Matsumoto; Terumitsu Hasebe
Journal:  Biology (Basel)       Date:  2021-12-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.